Literature DB >> 19115138

In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis.

R G Vitale1, M Perez-Blanco, G S De Hoog.   

Abstract

The antifungal activity of six drugs was evaluated against 41 clinical and environmental isolates of Cladophialophora carrionii and its sister species C. yegresii. Drugs tested, including their ranges, were: 16-0.016 microg/ml for amphotericin B (AMB), itraconazole (ITZ) and voriconazole (VCZ), 8-0.008 microg/ml for terbinafine (TBF), and 64-0.063 microg/ml for flucytosin (5-FC) and fluconazole (FCZ). Strains were tested according to the CLSI guidelines (M38A). The MIC Gmeans for clinical strains in microg/ml were; 0.02 for TBF and ITZ, 0.07 microg/ml for VCZ, 0.49 for 5FC, 6.14 for FCZ and 9.42 for AMB. The MFC Gmeans in microg/ml were; 0.04 for TBF, 0.13 for ITZ, 0.72 for VCZ, 18.83 for 5FC, 36.16 for FCZ and 31.35 for AMB. The most active drugs against the fungi were TBF, ITZ, VCZ and 5FC. However, for all drugs more than two dilution steps were noted between the MIC and the MFC, indicating fungistatic activity. Despite in vitro susceptibility of C. carrionii to antifungal agents, the efficacy of therapy was shown to be not optimal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19115138     DOI: 10.1080/13693780802566333

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  11 in total

1.  In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis.

Authors:  S Deng; G S de Hoog; H Badali; L Yang; M J Najafzadeh; B Pan; I Curfs-Breuker; J F Meis; W Liao
Journal:  Antimicrob Agents Chemother       Date:  2013-02-04       Impact factor: 5.191

2.  Subcutaneous fungal infections.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2012-10       Impact factor: 3.725

Review 3.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 4.  Phaeohyphomycoses, emerging opportunistic diseases in animals.

Authors:  S Seyedmousavi; J Guillot; G S de Hoog
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

Review 5.  Melanized fungi in human disease.

Authors:  Sanjay G Revankar; Deanna A Sutton
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

6.  1,10-phenanthroline inhibits the metallopeptidase secreted by Phialophora verrucosa and modulates its growth, morphology and differentiation.

Authors:  Marcela Queiroz Granato; Priscila de Araújo Massapust; Sonia Rozental; Celuta Sales Alviano; André Luis Souza dos Santos; Lucimar Ferreira Kneipp
Journal:  Mycopathologia       Date:  2014-12-12       Impact factor: 2.574

7.  In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.

Authors:  Mohammad J Najafzadeh; Hamid Badali; Maria Teresa Illnait-Zaragozi; G Sybren De Hoog; Jacques F Meis
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

Authors:  S Deng; W Lei; G S de Hoog; L Yang; R G Vitale; H Rafati; M Seyedmousavi; A Tolooe; H van der Lee; W Liao; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 9.  Challenges in the therapy of chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Daniel Wagner de C L Santos
Journal:  Mycopathologia       Date:  2013-05-02       Impact factor: 2.574

10.  Novel treatment using topical malachite green for nasal phaeohyphomycosis caused by a new Cladophialophora species in a cat.

Authors:  Ian J Brooks; Stuart A Walton; Justin Shmalberg; Autumn Harris
Journal:  JFMS Open Rep       Date:  2018-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.